Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy

Atherosclerosis

Volumn 223, Issue 1, 2012, Pages 197-203

  Bellia, Alfonso ^a   Rizza, Stefano ^a   Lombardo, Marco Felice ^a   Donadel, Giulia ^a   Fabiano, Rossella ^a   Andreadi, Katia ^a   Quon, Michael J ^b   Sbraccia, Paolo ^a   Federici, Massimo ^a   Tesauro, Manfredi ^a   Cardillo, Carmine ^c   Lauro, Davide ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF MARYLAND   (United States)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Insulin secretion; Insulin resistance; Statins; Type 2 diabetes

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEPTIN; LIPID; METFORMIN; ROSUVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; ITALY; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADIPONECTIN; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; FLUOROBENZENES; GLUCOSE CLAMP TECHNIQUE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HOSPITALS, UNIVERSITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LEPTIN; LIPIDS; MALE; MIDDLE AGED; PYRIMIDINES; ROME; SIMVASTATIN; SINGLE-BLIND METHOD; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863092923     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.04.015     Document Type: Article

References (28)

1. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
2. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109:39-43.
3. Sattar N., Preiss D., Murray H.M., Welsh P., Buckley B.M., de Craen A.J., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
4. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002, 287:2563-2569.
5. Yada T., Nakata M., Shiraishi T., Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999, 126:1205-1213.
6. Xia F., Xie L., Mihic A., Gao X., Chen Y., Gaisano H.Y., et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology 2008, 149:5136-5145.
7. Chamberlain L.H. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS 2001, 507:357-361.
8. Mäuser W., Perwitz N., Meier B., Fasshauer M., Klein J. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur J Pharmacol 2007, 564:37-46.
9. Takaguri A., Satoh K., Itagaki M., Tokumitsu Y., Ichihara K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J Pharmacol Sci 2008, 107:80-89.
10. Collins R., Armitage J., Parish S., Sleigh P., Peto R. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016. Heart Protection Study Collaborative Group.
11. Hwu C.M., Kwok C.F., Chen H.S., Shih K.C., Lee S.H., Hsiao L.C., et al. Lack of effect of simvastatin on insulin sensitivity in type 2 diabetic patients with hypercholesterolaemia: results from a double-blind, randomized, placebo-controlled crossover study. Diabet Med 1999, 16:749-754.
12. Szendroedi J., Anderwald C., Krssak M., Bayerle-Eder M., Esterbauer H., Pfeiler G., et al. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. Diabetes Care 2009, 32:209-214.
13. Ohrvall M., Lithell H., Johansson J., Vessby B. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism 1995, 44:212-217.
14. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207. JUPITER Study Group.
15. Kostapanos M.S., Milionis H.J., Agouridis A.D., Rizos C.V., Elisaf M.S. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract 2009, 63:1308-1313.
16. ter Avest E., Abbink E.J., de Graaf J., Tack C.J., Stalenhoef A.F. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest 2005, 35:558-564.
17. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:214-223.
18. Matthews D.R., Hosker J.P., Rudenski A.S., Burnett M.A., Darling P., Bown E.G., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
19. Barac A., Campia U., Panza J.A. Methods for evaluating endothelial function in humans. Hypertension 2007, 49:748-760.
20. Baker W.L., Talati R., White C.M., Coleman C.I. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010, 87:98-107.
21. Mabuchi H., Higashikata T., Kawashiri M., Katsuda S., Mizuno M., Nohara A., et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 2005, 12:111-119.
22. Maeda T., Horiuchi N. Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation. J Biochem 2009, 145:771-781.
23. Chu N.F., Spiegelman D., Hotamisligil G.S., Rifai N., Stampfer M., Rimm E.B. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 2001, 157:495-503.
24. Morioka T., Asilmaz E., Hu J., Dishinger J.F., Kurpad A.J., Elias C.F., et al. Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice. J Clin Invest 2007, 117:2860-2868.
25. Shimabukuro M., Wang M.Y., Zhou Y.T., Newgard C.B., Unger R.H. Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci USA 1998, 95:9558-9561.
26. Kim J.A., Montagnani M., Koh K.K., Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
27. Laufs U., Endres M., Custodis F., Gertz K., Nickenig G., Liao J.K., et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 2000, 102:3104-3110.
28. Monroy A., Kamath S., Chavez A.O., Centonze V.E., Veerasamy M., Barrentine A., et al. Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 2009, 52:2169-2181.